Abstract
Protein Tyrosine kinases (TKs) play important roles in regulating the most fundamental cell processes, such as the cell cycle, proliferation, differentiation, motility, and cell death or survival. In many tumor cells, key TKs may no longer be adequately controlled, and excessive phosphorylation sustains signal transduction pathways in an activated state. Imatinib mesylate is an oral multitargeted tyrosine kinase inhibitor with antitumor activity. It recently received approval from the US Food and Drug Administration for the treatment of patients with BCR/ABL translocation defining chronic myeloid leukaemia, and subsequently for the treatment of patients with KIT (CD117)-positive non-resectable and/or metastatic malignant gastrointestinal stromal tumors. It has also shown promising clinical activity against other advanced solid tumors. The review provides an updated summary of emerging clinical experience with this promising new anticancer agent.
Keywords: Tyrosine kinases, imatinib mesylate, targeted-therapy, ABL-BRL, c-kit, solid tumors
Current Enzyme Inhibition
Title: Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Volume: 3 Issue: 4
Author(s): Carlo Smirne, Anna Carbone, Tiziana Scirelli and Graziella Bellone
Affiliation:
Keywords: Tyrosine kinases, imatinib mesylate, targeted-therapy, ABL-BRL, c-kit, solid tumors
Abstract: Protein Tyrosine kinases (TKs) play important roles in regulating the most fundamental cell processes, such as the cell cycle, proliferation, differentiation, motility, and cell death or survival. In many tumor cells, key TKs may no longer be adequately controlled, and excessive phosphorylation sustains signal transduction pathways in an activated state. Imatinib mesylate is an oral multitargeted tyrosine kinase inhibitor with antitumor activity. It recently received approval from the US Food and Drug Administration for the treatment of patients with BCR/ABL translocation defining chronic myeloid leukaemia, and subsequently for the treatment of patients with KIT (CD117)-positive non-resectable and/or metastatic malignant gastrointestinal stromal tumors. It has also shown promising clinical activity against other advanced solid tumors. The review provides an updated summary of emerging clinical experience with this promising new anticancer agent.
Export Options
About this article
Cite this article as:
Smirne Carlo, Carbone Anna, Scirelli Tiziana and Bellone Graziella, Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions, Current Enzyme Inhibition 2007; 3 (4) . https://dx.doi.org/10.2174/157340807782330246
DOI https://dx.doi.org/10.2174/157340807782330246 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters Meet Our Editorial Board Member
Current Cancer Drug Targets CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets The Current Chemical Utility of Marine and Terrestrial Filamentous Fungi in Side-Chain Chemistry
Current Organic Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets